£119.99

It has never been this cheap. We have no record of a lower price.

£120 today · cheaper than every other day in the last 3 months

Springer Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer (AAPS Advances in the Pharmaceutical Sciences Series, 17)

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 64 days · 64 data points (no recent data)

Historical
Generating forecast…
£119.99 £113.99 £116.39 £118.79 £121.19 £123.59 £125.99 27 July 2026 11 August 2026 27 August 2026 12 September 2026 28 September 2026
View at Amazon ↗

Price data last checked 23 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 64 days • 1 price levels

Days at Price
64 days 0 16 32 48 64 £120 Days at Price

Price Analysis

Most common price: £120 (64 days, 100.0%)

Price range: £120 - £120

Price levels: 1 different prices over 64 days

Description

The field of antibody-drug conjugates (ADCs) has undergone remarkable advancements in recent years, marked by significant progress in both drug approvals and ongoing clinical development. Since the approval of the first ADC in 2010 (gemtuzumab ozogamicin, Mylotarg®), the landscape has expanded dramatically. Today, there are 11 FDA-approved ADCs, targeting a variety of cancers across multiple indications. The approved ADCs include a range of payloads, linkers, and antibodies, each optimized for a variety of specific therapeutic targets. The increasing diversity of ADCs reflects the growing potential of these innovative treatments to address a wide array of malignancies, from hematologic cancers to solid tumors. This book aims to provide a comprehensive overview of the current state of the ADC field including the latest developments, challenges, and emerging trends, comprising expertise from a broad range of disciplines from basic research, industry, clinical practice and regulatory affairs. We explore not only the scientific and technical aspects of ADC design—such as payloads, linkers, and antibody selection—but also the developmental hurdles and regulatory complexities that influence the success of ADCs in clinical practice. Real-world examples of ADCs that have made it from the lab to the clinic offer invaluable insights into the trials and triumphs that shape this dynamic field. It is our hope that this book will serve as both a valuable resource for experts in the field and an accessible introduction for those new to the exciting world of ADCs.

Product Specifications

Barcode

No barcode data available

Similar Products You Might Like

Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer: 17 (AAPS Advances in the Pharmaceutical Sciences Series)
92% match

Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer: 17 (AAPS Advances in the Pharmaceutical Sciences Series)

Springer

£86.15 07 Aug 2026
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins (Milestones in Drug Therapy)
87% match

Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins (Milestones in Drug Therapy)

Springer

£113.77 05 Aug 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
82% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£113.76 06 Aug 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
81% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£108.01 10 Aug 2026
Enzyme-Prodrug Strategies for Cancer Therapy
81% match

Enzyme-Prodrug Strategies for Cancer Therapy

Springer

£149.87 05 Aug 2026
Bispecific Antibodies
81% match

Bispecific Antibodies

Springer

£124.06 12 Aug 2026
Cellular Therapies for Cancer Treatment: Advancements in Drug Delivery Strategies
80% match

Cellular Therapies for Cancer Treatment: Advancements in Drug Delivery Strategies

Elsevier

£141.99 06 Aug 2026
Nutraceuticals and Cancer
80% match

Nutraceuticals and Cancer

Springer

£113.76 05 Aug 2026
Current Applications for Overcoming Resistance to Targeted Therapies: 20 (Resistance to Targeted Anti-Cancer Therapeutics, 20)
80% match

Current Applications for Overcoming Resistance to Targeted Therapies: 20 (Resistance to Targeted Anti-Cancer Therapeutics, 20)

Springer

£76.42 08 Aug 2026
Pharmaceutical Perspectives of Cancer Therapeutics
80% match

Pharmaceutical Perspectives of Cancer Therapeutics

Springer

£179.99 08 Aug 2026
Systemic Radiotherapy with Monoclonal Antibodies: Options and Problems: 141 (Recent Results in Cancer Research, 141)
80% match

Systemic Radiotherapy with Monoclonal Antibodies: Options and Problems: 141 (Recent Results in Cancer Research, 141)

Springer

£76.42 08 Aug 2026
Cancer Vaccines - Harnessing Immunotherapy and Genetic Engineering for Universal Cancer Prevention: 2025 (Advanced Bio-Medical CRISPR Technologies)
80% match

Cancer Vaccines - Harnessing Immunotherapy and Genetic Engineering for Universal Cancer Prevention: 2025 (Advanced Bio-Medical CRISPR Technologies)

£55.54 14 Sep 2026
79% match

Biosimilars in Cancer

Academic Press

£153.99 04 Aug 2026
Cancer Targeting Therapies: Conventional and Advanced Perspectives (Drugs and the Pharmaceutical Sciences)
79% match

Cancer Targeting Therapies: Conventional and Advanced Perspectives (Drugs and the Pharmaceutical Sciences)

CRC Press

£90.32 15 Sep 2026
Targeted Radionuclide Tumor Therapy: Biological Aspects
79% match

Targeted Radionuclide Tumor Therapy: Biological Aspects

Springer

£139.97 04 Aug 2026
Advances in Pharmaceutical Technology
79% match

Advances in Pharmaceutical Technology

MTG

£63.96 15 Sep 2026
Converging Technologies in Precision Oncology: The Future of Cancer Care
79% match

Converging Technologies in Precision Oncology: The Future of Cancer Care

Springer

£109.99 13 Sep 2026
Cancer Immunotherapy: Immune Suppression and Tumor Growth
79% match

Cancer Immunotherapy: Immune Suppression and Tumor Growth

Academic Press

£88.00 13 Aug 2026
Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy
79% match

Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy

Elsevier

£135.56 05 Aug 2026
Translating Molecular Biomarkers into Clinical Assays: Techniques and Applications: 21 (AAPS Advances in the Pharmaceutical Sciences Series, 21)
79% match

Translating Molecular Biomarkers into Clinical Assays: Techniques and Applications: 21 (AAPS Advances in the Pharmaceutical Sciences Series, 21)

Springer

£108.01 17 Aug 2026
An Introduction to Bioanalysis of Biopharmaceuticals: 57 (AAPS Advances in the Pharmaceutical Sciences Series, 57)
79% match

An Introduction to Bioanalysis of Biopharmaceuticals: 57 (AAPS Advances in the Pharmaceutical Sciences Series, 57)

Springer

£97.88 12 Sep 2026
Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science
79% match

Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science

Springer

£108.01 07 Aug 2026
Cancer Drug Discovery: Science and History
79% match

Cancer Drug Discovery: Science and History

Springer

£113.76 05 Aug 2026
Immunotherapy for Gastrointestinal Cancer
79% match

Immunotherapy for Gastrointestinal Cancer

Springer

£99.11 08 Aug 2026